(Q36999332)

17 August 2017

1 reference

title

Ursodeoxycholic acid in chronic hepatitis C (English)

1 reference

17 August 2017

1 reference

1 reference

1

Raoul Poupon

0 references

author name string

Lawrence Serfaty

series ordinal

2

1 reference

PMC publication ID

2095696

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

56

1 reference

17 August 2017

12

1 reference

17 August 2017

1652-1653

1 reference

Bile Acids Promote the Expression of Hepatitis C Virus in Replicon-Harboring Cells

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

The cirrhotic hepatocyte: navigating between Scylla and Charybdis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095696

The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17998321

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17998321

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/GUT.2007.130484

1 reference

17 August 2017

1 reference

PMC publication ID

2095696

17 August 2017

PubMed publication ID

17998321

1 reference

PMC publication ID

2095696